MERCK & CO INC's ticker is MRK and the CUSIP is 58933Y105. A total of 3,422 filers reported holding MERCK & CO INC in Q2 2024. The put-call ratio across all filers is 0.80 and the average weighting 0.6%.
About MERCK & CO INC
Merck & Co Inc. is a leading pharmaceutical company that has been in operation for over a century. The company is known for its innovative research and development of drugs that have helped to improve the health and well-being of millions of people around the world.
Merck & Co Inc. has a strong pipeline of drugs that are in various stages of development. The company's focus on research and development has helped it to stay ahead of its competitors in the pharmaceutical industry. Merck & Co Inc. has a number of drugs that are currently in clinical trials, and the company is optimistic about the potential of these drugs to treat a range of diseases.
One of the key strengths of Merck & Co Inc. is its commitment to sustainability. The company has set ambitious goals to reduce its environmental impact and to promote social responsibility. Merck & Co Inc. has been recognized for its efforts in sustainability, and the company is committed to continuing to make progress in this area.
Merck & Co Inc. has a strong financial position, with a solid balance sheet and a history of consistent earnings growth. The company's strong financial position has allowed it to invest in research and development, and to pursue strategic acquisitions that have helped to expand its product portfolio.
Overall, Merck & Co Inc. is a well-respected pharmaceutical company that has a strong track record of innovation and success. With a focus on sustainability and a commitment to research and development, the company is well-positioned for continued growth and success in the years ahead.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $3,930,641 | -1.2% | 31,750 | +5.3% | 0.33% | -10.1% |
| Q1 2024 | $3,977,160 | +20.8% | 30,141 | -0.2% | 0.37% | +19.9% |
| Q4 2023 | $3,292,310 | +4.8% | 30,195 | -1.1% | 0.31% | -7.3% |
| Q3 2023 | $3,142,919 | -7.4% | 30,528 | +3.7% | 0.33% | -4.6% |
| Q2 2023 | $3,395,274 | -42.4% | 29,425 | -46.6% | 0.35% | +5.2% |
| Q1 2023 | $5,898,249 | -24.8% | 55,145 | -22.0% | 0.33% | -6.0% |
| Q4 2022 | $7,848,211 | +57.5% | 70,736 | +22.3% | 0.35% | +19.0% |
| Q3 2022 | $4,983,000 | +72.3% | 57,857 | +84.9% | 0.29% | +14.4% |
| Q2 2022 | $2,892,000 | -13.9% | 31,294 | -23.6% | 0.26% | +36.0% |
| Q1 2022 | $3,359,000 | +46.4% | 40,939 | +36.7% | 0.19% | -2.6% |
| Q4 2021 | $2,295,000 | +8.9% | 29,941 | +9.5% | 0.19% | +14.8% |
| Q1 2021 | $2,108,000 | -3.4% | 27,345 | +2.5% | 0.17% | -15.9% |
| Q4 2020 | $2,182,000 | – | 26,677 | – | 0.20% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Radnor Capital Management, LLC | 635,889 | $53,529,000 | 17.54% |
| Aristotle Atlantic Partners, LLC | 652,010 | $54,886,000 | 15.81% |
| SRB CORP | 1,844,014 | $155,229,000 | 13.64% |
| R. G. NIEDERHOFFER CAPITAL MANAGEMENT INC | 13,800 | $1,162,000 | 10.31% |
| Naman Capital Ltda | 120,000 | $10,102,000 | 9.96% |
| Ashburton (Jersey) Ltd | 210,924 | $17,756,000 | 8.76% |
| PARUS FINANCE (UK) Ltd | 149,840 | $12,614,000 | 7.94% |
| ANTIPODES PARTNERS Ltd | 1,768,365 | $148,861,000 | 7.10% |
| Circle Wealth Management, LLC | 389,055 | $32,751,000 | 6.97% |
| TERRIL BROTHERS, INC. | 218,273 | $18,374,000 | 6.20% |